Ratings Groupe Berkem

Equities

ALKEM

FR00140069V2

Real-time Euronext Paris Other stock markets 04:48:00 2024-07-03 am EDT			5-day change	1st Jan Change
1.805 ^EUR	+1.40%		-0.82%	-41.01%

May. 13	Groupe Berkem Unveils BiombalanceTM and Pineol Premium, Two Active Ingredients from Its New Nutraceutical Range	CI
Apr. 30	Groupe Berkem Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Strengths

The company's profit outlook over the next few years is a strong asset.
The company appears to be poorly valued given its net asset value.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company does not generate enough profits, which is an alarming weak point.
The company is in debt and has limited leeway for investment
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
GROUPE BERKEM	-41.01%	33.63M	-
ELI LILLY AND COMPANY	+55.63%	816B	C+
NOVO NORDISK A/S	+39.45%	634B	B
JOHNSON & JOHNSON	-7.53%	351B	C+
MERCK & CO., INC.	+15.84%	323B	B-
ABBVIE INC.	+6.83%	293B	C+
ASTRAZENECA PLC	+13.45%	238B	B+
ROCHE HOLDING AG	+0.61%	222B	A+
NOVARTIS AG	+13.35%	218B	B-
AMGEN INC.	+7.75%	167B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes